HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ST1326

Also Known As:

(R)-N-(tetradecylcarbamoyl)aminocarnitine

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Quaternary Ammonium Compounds: 136
    - Trimethyl Ammonium Compounds: 1
      - Carnitine: 4291
        ST1326: 4

Experts

1.	Nicolai, Raffaella: 2 articles (10/2015 - 04/2013)
2.	Peluso, Gianfranco: 2 articles (10/2015 - 04/2013)
3.	Allegretti, Matteo: 1 article (10/2015)
4.	Calarco, Anna: 1 article (10/2015)
5.	Foà, Robin: 1 article (10/2015)
6.	Konopleva, Marina: 1 article (10/2015)
7.	Licchetta, Roberto: 1 article (10/2015)
8.	Mirabilii, Simone: 1 article (10/2015)
9.	Ricciardi, Maria Rosaria: 1 article (10/2015)
10.	Samudio, Ismael: 1 article (10/2015)

Related Diseases

1.	Diabetes Mellitus 04/01/2006 - "The structure of CPT-2 in complex with the generic CPT inhibitor ST1326 ([R]-N-[tetradecylcarbamoyl]-aminocarnitine), a substrate analog mimicking palmitoylcarnitine and currently in clinical trials for diabetes mellitus treatment, was solved at 2.5 A resolution. "
2.	Leukemia 10/15/2015 - "By real-time metabolic analysis, we documented that ST1326 inhibited FAO in leukemia cell lines associated with a dose- and time-dependent cell growth arrest, mitochondrial damage, and apoptosis induction. " 10/15/2015 - "In this issue of Blood, Ricciardi et al report a novel fatty acid oxidation (FAO) inhibitor, ST1326, that effectively inhibits proliferation, survival, and chemoresistance in leukemia cell lines and primary samples." 10/15/2015 - "Because the carnitine palmitoyl transferase 1a (CPT1a) is a protein that catalyzes the rate-limiting step of FAO, here we investigated the in vitro antileukemic activity of the novel CPT1a inhibitor ST1326 on leukemia cell lines and primary cells obtained from patients with hematologic malignancies. "
3.	Hematologic Neoplasms (Hematological Malignancy) 10/15/2015 - "Because the carnitine palmitoyl transferase 1a (CPT1a) is a protein that catalyzes the rate-limiting step of FAO, here we investigated the in vitro antileukemic activity of the novel CPT1a inhibitor ST1326 on leukemia cell lines and primary cells obtained from patients with hematologic malignancies. "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/15/2015 - "Data obtained on primary hematopoietic malignant cells confirmed the FAO inhibition and cytotoxic activity of ST1326, particularly on acute myeloid leukemia cells. "
5.	Neoplasms (Cancer) 04/03/2013 - "Moreover, treatment with ST1326 in Eµ-myc transgenic mice prevented tumor formation (P = .01), by selectively impairing the growth of spleen-derived primary B cells overexpressing c-myc (wild-type cells + ST1326 vs. Eµ-myc cells + ST1326: 99.75% vs. 57.5%, difference = 42.25, 95% confidence interval of difference = 14% to 70%; P = .01). "

Related Drugs and Biologics

1.	ST1326
2.	Palmitoylcarnitine
3.	2- cyclohexylidenhydrazo- 4- phenyl- thiazole
4.	Transferases
5.	Proteins (Proteins, Gene)
6.	Fatty Acids (Saturated Fatty Acids)
7.	Carnitine (L-Carnitine)